The treatment of multiple myeloma (MM) has entered the era of immunotherapy. In particular, the emergence of Chimeric Antigen Receptor T-cell (CAR-T) therapy has significantly improved the prognosis of patients with relapsed/refractory multiple myeloma (R/R MM). However, challenges such as resistance caused by antigen loss, prolonged manufacturing cycles (vein-to-vein time), and potential severe toxicities remain major hurdles in clinical practice. At a recent academic conference, Professor Yi Lin, the Jess S. Jackson Family Professor of Cancer Research at Mayo Clinic, shared in-depth insights on the theme "CAR-T Cell Manufacturing: Scientific Progress and Technological Innovation." This article aims to extract the core academic viewpoints from Professor Yi Lin's report and explore how iterations in CAR-T manufacturing processes translate into clinical benefits.01 Paradigm Shift in Manufacturing Platforms: From Conventional Processes to Rapid/Instant Manufacturing
Currently, conventional CAR-T manufacturing processes approved by global regulatory agencies face the challenge of long production cycles. From leukapheresis, ex-vivo expansion, and quality control to infusion, the manufacturing phase alone typically takes about 10 days. Including logistics and testing, patients often wait for several weeks, which poses a significant risk for myeloma patients with rapidly progressing disease.
Professor Yi Lin pointed out that emerging rapid manufacturing platforms (such as Fast-CAR, T-Charge, Instant CAR, etc.) are reshaping this process. • Process Optimization: These platforms shorten the ex-vivo culture time of T cells to 3 days or even less, and some processes even eliminate the ex-vivo expansion step. • Biological Advantages: Early translational research data indicate that the less time T cells spend outside the body, the stronger their T cell fitness. Compared to the cell exhaustion caused by long-term ex-vivo expansion, rapidly manufactured CAR-T cells exhibit superior phenotypes and demonstrate stronger expansion potential and persistence after infusion. • Clinical Significance: This not only significantly shortens the patient’s vein-to-vein time but also provides a biological basis for improving long-term remission rates by enhancing cell quality.
02 Strategies to Overcome Antigen Escape: Development of Next-Generation Targets Beyond BCMA
Although CAR-T therapies targeting B-cell maturation antigen (BCMA) have achieved great success, subsequent antigen escape has become a primary mechanism of relapse. Professor Yi Lin summarized several forms of antigen escape: trogocytosis, biallelic genetic loss, and BCMA protein mutations.
To address these resistance mechanisms, new targets such as GPRC5D, SLAMF7, and FCRH5 have entered clinical development, with GPRC5D having the most comprehensive data: • MCAR109 Study: In a single-center Phase I clinical trial involving a heavily pretreated patient population where over 90% were triple-refractory and nearly half had extramedullary disease, GPRC5D CAR-T demonstrated significant activity. With a median follow-up of nearly 3 years, the overall response rate (ORR) reached 71%, with the majority of patients achieving deep responses and minimal residual disease (MRD) negativity. • OriCAR-017 Study: Data from China further validated the potential of this target. In a small sample exploration of 10 patients, similarly high ORR and MRD negativity rates were observed. • Safety Considerations: Compared to BCMA-targeted drugs, GPRC5D CAR-T possesses unique mucocutaneous toxicities, including nail changes, dysgeusia, and cerebellar toxicity. Professor Yi Lin emphasized that as follow-up time extends, managing these toxicities that affect quality of life will be a focus of clinical research.
03 Structural Engineering Optimization: D-domain Design to Enhance Drug Safety and Efficacy
Beyond switching targets, the optimization of the CAR molecule’s own structure is a core innovation. Professor Yi Lin highlighted the D-domain CAR-T technology, which is a novel structure distinct from traditional single-chain variable fragment (scFv) fragments. • Engineering Advantages: The D-domain is a much smaller protein with a faster folding rate, which enables higher transduction efficiency during the manufacturing process and reduces the required total number of starting T cells. • Pharmacokinetic Characteristics: This smaller structure is hypothesized to better penetrate tumor tissues. More importantly, it allows for a faster off-rate after engaging BCMA. Research suggests that moderate binding affinity can prevent rapid T cell exhaustion caused by excessive signaling. • Safety Improvements: Existing BCMA CAR-Ts have shown rare but severe cerebellar toxicities, Parkinsonism, and enterocolitis in clinical settings. Preliminary data suggest that the D-domain design may reduce the risk of such severe neurotoxicities by optimizing signal strength, and related Phase I/II trials are currently progressing.
04 Synergistic Enhancement: Clinical Progress of Dual-Targeting Strategies
To further prevent disease progression caused by single-target loss, dual-targeting or tandem CAR-T schemes have become research hotspots. Professor Yi Lin introduced various construction modes, including co-administration, co-transduction, and single-vector bicistronic expression. • AZD0120 (formerly GC012F): This is a dual-specific CAR-T targeting both BCMA and CD19. The product incorporates the Fast-CAR manufacturing platform (manufacturing cycle < 3 days). • Data Interpretation: In clinical studies involving 23 patients (including those with prior exposure to BCMA-targeted therapy), the ORR was excellent, with a complete response (CR) rate in the 78% range and very high MRD negativity rates. In terms of safety, CRS (Cytokine Release Syndrome) and ICANS (Immune Effector Cell-Associated Neurotoxicity Syndrome) were mostly low-grade. This strategy is expected to build a higher anti-tumor barrier by covering multiple antigens simultaneously.
05 Disruptive Innovation: Prospective Exploration of In-Vivo CAR-T Transduction
At the end of the report, Professor Yi Lin looked forward to the most cutting-edge in-vivo CAR-T technology. This technology aims to modify T cells in situ within the patient’s body by directly infusing lentiviral-based vectors or engineered particles. • Technical Principle: This approach utilizes specifically modified viral particles to accurately identify and transduce resting T cells in the circulatory system, converting them into CAR-positive T cells. • Trend Toward De-chemotherapy: The greatest innovation lies in the elimination of lymphodepletion chemotherapy. Because this process does not require the infusion of large-scale ex-vivo expanded cells, it utilizes the patient’s own immune environment. • Early Clinical Data: KLN1010 (In-myCAR study) has initially dosed 18 patients. Data show that without preconditioning chemotherapy, some patients still maintained MRD negativity beyond 3 months of follow-up. Although one relapse has been observed, this opens a completely new path for the “de-infrastructure” and “de-toxicity” of CAR-T therapy.
Expert Conclusion and Future Outlook
Professor Yi Lin concluded that CAR-T in the field of multiple myeloma is undergoing an evolution from “single target” to “precision engineering.” By shortening manufacturing cycles, developing alternative targets like GPRC5D, optimizing the off-rate of CAR molecules, and exploring in-vivo transduction technologies, we hope to improve efficacy while significantly reducing drug side effects and increasing treatment accessibility. Future research will focus on the accumulation of long-term follow-up data to determine if these technological innovations can translate into long-term progression-free survival (PFS) benefits for patients.
Expert Profile
Professor Yi Lin
The Jess S. Jackson Family Professor of Cancer Research at Mayo Clinic (Rochester). Professor Lin has significant international influence in the fields of cellular therapy, multiple myeloma, and lymphoma translational research, leading and participating in multiple pivotal CAR-T clinical trials that have changed clinical practice.
